You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]
Glucotrack
Glucotrack, Lōkahi secure financing for completed merger
Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with Lōkahi Therapeutics. The bridge financing, designed to support their strategic growth objectives, allows for the completion of the combination to proceed. Glucotrack did not disclose the terms of the financing. Earlier this week, the company’s announced their […]
Glucotrack combines with Lōkahi Therapeutics to become CBGM subsidiary
Glucotrack (Nasdaq:GCTK) announced that it completed a strategic business combination with Lōkahi Therapeutics. The companies structured the combination so that Lōkahi becomes the operating and controlling business of the combined company. It now leverages Glucotrack’s continuous blood glucose monitoring (CBGM) business as a wholly owned subsidiary. According to a news release, the combined organization integrates […]
Glucotrack expands IP to cover novel glucose monitor sensor architectures
Glucotrack (Nasdaq:GCTK) announced today that it secured new intellectual property allowance protecting its continuous blood glucose monitor (CBGM). The patent application, titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient,” was allowed by the U.S. Patent and Trademark Office (USPTO), expanding the IP protecting the CBGM as Glucotrack looks to advance […]
Glucotrack CEO explains tech behind long-term CBGM implant
Glucotrack (Nasdaq:GCTK) has made great strides over the past several years as it advances its implantable continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that […]
Glucotrack submits long-term implantable CBGM for FDA IDE
Glucotrack (Nasdaq:GCTK) announced today that it submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE. FDA IDE (investigational device exemption) would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of […]
More data backs Glucotrack long-term implantable CBGM
Glucotrack (Nasdaq:GCTK) today announced another publication of data supporting its long-term implantable glucose sensor. The latest data, published in The Journal of Diabetes Research, follows a publication last week supporting the system’s feasibility. This study evaluated the long-term accuracy and stability of the fully implantable blood glucose monitoring (CBGM) system in an in-vivo ovine model. […]
Gluckotrack study supports feasibility of long-term CGM implant
Glucotrack (Nasdaq:GCTK) today announced the publication of a peer-reviewed scientific article evaluating its long-term glucose sensor. The article, published in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal, demonstrated the long-term in-vitro stability of the electrochemical glucose sensors used in the company’s fully implantable continuous blood glucose monitoring (CBGM) system. The company said […]
Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2
Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor (CBGM). The Glucotrack device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, […]
Glucotrack picks up new patents for continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) platform. The U.S. Patent and Trademark Office (USPTO) issued Patent Nos. US 12,453,494, US 12,458,257 and US 12,458,258. These patents strengthen the company’s competitive position and intellectual property protection as it advances its CBGM system toward commercialization. Glucotrack’s […]
